Skip to main content
OACCU logo

OACCU · Oaktree Acquisition Corp. III Life Sciences · Documents

Track OACCU — free
$10.75 At close · Nov 13
Market Cap
$142.06M
Shares
13.25M
Volume · Nov 13 2500 Avg daily vol (5 sessions) 1102

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net income $7.29M 10-K filed Mar 26, 2026 Quarterly report New FY2026 Q3 Net loss $452.55K 10-Q filed Nov 13, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Combination deadline extended as redemptions cut trust to $85.0 million

Oaktree Acquisition Corp. III Life Sciences extended its combination deadline to November 25, 2026, after holders of 11,331,102 public shares redeemed them for an aggregate $122,435,287, leaving an approximately $85.0 million trust balance and substantial doubt about going concern.

Net loss $452.55K
Read from the MD&A section
4 source passages
References in this Quarterly Report on Form 10-Q (the “Report”) to “we,” “us” or the “Company” refer to Oaktree Acquisition Corp. III Life Sciences. On October 23, 2026, we held an extraordinary general meeting in lieu of an annual general meeting of shareholders (the “Extension Meeting”), at which our shareholders approved an amendment to our amended and restated memorandum and articles of association (the “Articles Amendment”) to extend the date by which we have to consummate a business combination from October 25, 2026 to November 25, 2026, and to allow us, if requested by the Sponsor, to further extend such date on a monthly basis up to May 25, 2027 without another shareholder vote (the “Extension,” and such period, as so extended, the “Combination Period”). In connection with the Extension Meeting, holders of 11,331,102 public shares exercised their right to redeem their shares for $10.81 per share, or an aggregate of $122,435,287, leaving 7,867,927 public shares outstanding and remaining trust balance of approximately $85.0 million. Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company’s ability to continue as a going concern. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 23
Shareholders extend deadline to November 25, 2026 amid redemptions

Oaktree Acquisition Corp. III Life Sciences shareholders approved extending its deadline from October 25, 2026 to November 25, 2026, with monthly extensions to May 25, 2027. Holders of 11,331,102 public shares redeemed them for approximately $122,435,287.

Unregistered sale of equity, Charter or bylaw amendment, or fiscal year change, Shareholder vote results
3 source passages
At the Extension Meeting, OAC’s shareholders approved an amendment to OAC’s amended and restated memorandum and articles of association (the “Articles Amendment”) to extend the date (the “Termination Date”) by which OAC has to consummate a business combination (a “Business Combination”) from October 25, 2026 (the “Original Termination Date”) to November 25, 2026 (the “Articles Extension Date”) for an aggregate extension period of up to seven months after the Original Termination Date, ending no later than May 25, 2027, unless the closing of a Business Combination shall have occurred prior thereto the holders of 11,331,102 Class A ordinary shares, $0.0001 par value, of OAC issued as part of the units initially sold in OAC’s initial public offering (the “Public Shares”) properly exercised their right to redeem their Public Shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.805 per Public Share, for an aggregate redemption amount of approximately $122,435,287. Open the document at this passage
Oct 16
Proxy statement DEFA14A
Proxy statement

Oaktree Acquisition Corp. III Life Sciences postponed its extraordinary general meeting from October 16, 2026 to October 23, 2026 to permit further solicitation and vote of proxies on extending the date to complete an initial business combination.

Oct 16
Current report 8-K
Regulation FD disclosure

Oaktree Acquisition Corp. III Life Sciences postponed its shareholder General Meeting, originally set for October 16, 2026, to October 23, 2026 at 10:00 a.m. Eastern Time to permit further proxy solicitation for the initial business combination extension proposal.

Oct 15
Proxy statement DEFA14A
Proxy statement

Oaktree Acquisition Corp. III Life Sciences reported 13,326,977 Class A shares tendered by the October 14, 2026 redemption deadline; conversion of 4,798,758 Class B shares into Class A shares would leave 11,254,791 Class A and 1,000 Class B shares outstanding.

Oct 15
Current report 8-K Events of Oct 14
Regulation FD disclosure

Oaktree Acquisition Corp. III Life Sciences reported 13,326,977 Class A ordinary shares tendered for redemption by 5:00 p.m., Eastern Time, on October 14, 2026; assuming redemptions and the Conversion, 11,254,791 Class A ordinary shares and 1,000 Class B ordinary shares will remain outstanding.

Oct 2
Proxy statement DEF 14A Meeting Oct 16, 2026
Proxy statement

Oaktree Acquisition Corp. III Life Sciences shareholders will vote to extend the Business Combination deadline from October 25, 2026 to November 25, 2026, with up to six optional one-month extensions ending no later than May 25, 2027, and to authorize meeting adjournment if needed.

Read from the first part of this long document
Sep 21
Proxy statement PRE 14A
Proxy statement

Oaktree Acquisition Corp. III Life Sciences seeks approval to extend its Business Combination deadline from October 25, 2026 to November 25, 2026, with up to six monthly extensions ending no later than May 25, 2027.

Read from the first part of this long document
2025
2024
Showing 1–25 of 25 documents
Key facts CIK 2029769 CUSIP G6717R104 13F (30d) 5 filings 5 filers Visit website Investor relations